Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
Brise has achieved several near-term milestones under a collaboration with a potential value of up to US $757 million plus royalties.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Brise Pharmaceuticals provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), covering two preclinical migraine programs.
The companies entered the agreement in 2024. Brise handles discovery, while AbbVie will lead global development and commercialization. The aggregate potential transaction value could reach up to US $757 million, including development, commercial, regulatory and sales milestones, plus royalties on future sales. Brise has already achieved several near-term milestones; the potential transaction value is not a disclosed payment received.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.AbbVie will lead global development and commercialization for two Brise preclinical migraine programs under the exclusive license agreement.
- Minor point. Forward-looking: it has not happened yet and may not happen.Aggregate potential transaction value could reach up to US $757 million, including development, commercial, regulatory and sales milestones.
- Minor point. Forward-looking: it has not happened yet and may not happen.Brise is eligible for royalties on future sales under the agreement.
- Minor pointBrise has already achieved several near-term milestones.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"This collaboration represents an important validation of our research platform in migraine and advances our mission to deliver potentially transformative medicines to patients," said Guochun Li, Chief Executive Officer of Brise Pharmaceuticals. "By partnering with a global leader like AbbVie, we can maximize the value of our discovery engine while continuing to invest in the next wave of innovative therapies."
Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory and sales milestones, could reach up to US
About Brise Pharmaceuticals
Founded in June 2021 in Shanghai, China, Brise Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering multi-modality therapeutics to transform the treatment landscape for debilitating pain conditions. The company's mission is to develop innovative and highly differentiated treatments, with the aim to systematically improve pain management and quality of life for patients living with migraine, nociceptive, neuropathic, and nociplastic pain.
Utilizing its research and discovery engine, Brise integrates small molecules and targeted antibodies therapeutics to modulate complex pain pathways at the molecular level. The company's pipeline currently features BR005, a novel China-originated, oral small-molecule, which is currently in pivotal clinical trials for acute treatment of migraine in adults, as well as a diverse portfolio of next-generation innovative therapeutic candidates advancing toward IND.
Learn more about the company's therapeutic pipelines at https://www.brisepharma.com/.
View original content:https://www.prnewswire.com/news-releases/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-to-advance-the-next-generation-of-migraine-therapies-302925660.html
SOURCE Brise Pharmaceuticals Co., Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the potential value of Brise Pharmaceuticals' agreement with AbbVie?
The aggregate potential transaction value could reach up to US $757 million, including development, commercial, regulatory and sales milestones, plus royalties on future sales.
What are Brise and AbbVie's roles in the migraine license agreement?
Brise is responsible for discovery efforts, while AbbVie will lead global development and commercialization for two of Brise's preclinical migraine programs. The companies entered the exclusive license agreement in 2024.